12/3/2018 NCI Metathesaurus



Anti-PD-L1 Monoclonal Antibody KN035 (CUI CL512904)

Suggest changes to this concept Add to Cart

Terms & Properties Synonym Details Relationships By Source View All		
Terms & Properties		
Concept Unique Identifier (CUI): CL512904		
NCI Thesaurus Code: C129714 (see NCI Thesaurus info)		
Semantic Type: Pharmacologic Substance		
NCIt Definition: An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, anti-PD-L1 monoclonal antibody KN035 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.		
Synonyms & Abbreviations: (see Synonym Details) Anti-PD-L1 MoAb KN035 Anti-PD-L1 Monoclonal Antibody KN035 KN 035 KN-035 KN035		
External Source Codes: NCI Thesaurus Code FDA UNII Code PDQ Closed Trial Search ID PDQ Open Trial Search ID	C129714 (see NCI Thesaurus info) ES1M06M6QH 784496 784496 (check for NCI PDQ open clinical trial info)	
Other Properties: Alue Name Contributing_Source Additional Concept Data: (none)		Source NCI
URL to Bookmark: https://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=CL512904		

NCI Home | Contact Us | Policies | Accessibility | FOIA
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov